Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.

This study is a prospective, single-center, single-arm, open-label research. It evaluates the safety and tolerability of 225Ac-TR2205 in patients with triple-negative breast cancer (TNBC), and assesses its radiation dosimetry and initial efficacy.

Participants needed: 15
Trial details
Phase: Early Phase 1Age: 18+Biological sex: FemaleType: InterventionalSponsor: Xiaorong SunUpdated: Jan 14, 2026Locations: 1
Eligibility criteria

Voluntary participation in the study and signing of the informed consent form. [+7]

Patients who received radiotherapy (except palliative radiotherapy) or chemother... [+9]

Read more
Status: Recruiting

A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to determine the safety and efficacy of 225Ac -labeled PSMA ligand(PSMA-XT) in the treatment of mCRPC

Participants needed: 40
Trial details
Phase: Phase 1Age: 18+Biological sex: MaleType: InterventionalSponsor: Xiaorong SunUpdated: Aug 24, 2025Locations: 1
Eligibility criteria

have the ability to understand and sign an approved informed consent form (ICF). [+10]

Previous treatment with any of the following within 6 months of enrollment: Stro... [+5]

Read more
Status: Recruiting

A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors

This is a single-center, single-arm clinical study to evaluate the safety, tolerability and preliminary efficacy of \[225Ac\]Ac-FAPI-XT injection in patients with FAP-positive advanced solid tumors.

Participants needed: 20
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Xiaorong SunUpdated: Aug 21, 2025Locations: 1
Eligibility criteria

≥18 years old Eastern Cooperative Oncology Group (ECOG) Performance status 0 to...

High intensity and large amounts of off-target uptake by FAP molecular imaging P...

Read more